



1645
RECEIVED
SEP 11 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2901

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : BIOPOLYMER MARKER INDICATIVE OF
DISEASE STATE HAVING A MOLECULAR
WEIGHT OF 1211 DALTONS
SERIAL NUMBER : 09/845,731
FILING DATE : 04/30/01
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1645
ATTORNEY DOCKET NO. : 2132.029

**COPY OF PAPERS
ORIGINALLY FILED**

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 9/3/02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

- ☒ Second Supplemental Preliminary Amendment
☒ Drawings; 2 sheets (relabeled substitute sheets of Fig. 2A and Fig. 2B)

Respectfully submitted,

Date: 9/3/2002

By: Ferris H. Lander

Ferris H. Lander
Registration No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



COPY OF PAPERS
ORIGINALLY FILED

#13
RECEIVED
SEP 11 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : BIOPOLYMER MARKER INDICATIVE OF
DISEASE STATE HAVING A MOLECULAR
WEIGHT OF 1211 DALTONS
SERIAL NUMBER : 09/845,731
FILING DATE : 04/30/01
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1645
ATTORNEY DOCKET NO. : 2132.029

#13/C
Plunkett
6/11/03
(NE)
Improper
no proper
marked-up

SECOND SUPPLEMENTAL PRELIMINARY AMENDMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 9-3-02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 19, lines 6-7, with the following rewritten paragraph:

--Figures 2A, and 2B represent alternative representations of the characteristic profile derived via SELDI/TOF MS of the disease specific marker of Figure 1.--